Galapagos enters into discovery collaboration with Idenix for infectious disease programs
Galapagos NV announced that it has entered into a collaboration with Idenix Pharmaceuticals, Inc. on selected hepatitis and HIV infectious disease programs. Pursuant to the collaboration, Galapagos' service division BioFocus will supply its proprietary SoftFocus® chemical compound collections to Idenix and provide expertise in the design and synthesis of biologically-directed compound collections. In addition, BioFocus will provide hit-to-lead and lead optimisation services. The entire discovery contract collaboration is worth up to $2.5 million over two years.
This arrangement represents Galapagos' first collaboration with Idenix. Under the terms of the agreement, Galapagos will receive undisclosed technology access fees for SoftFocus® collections, as well as a fee component for medicinal chemistry services plus success payments upon realization of certain objectives relating to the identification of pre-clinical candidates.
Other news from the department business & finance
